Eli Lilly received FDA approval for its once-daily weight-loss pill, immediately positioning the company to challenge Novo Nordisk in the lucrative GLP-1 market. The regulatory clearance sets the stage for direct competition between pharmaceutical giants as they battle for dominance in the $70 billion-plus weight loss and diabetes drug category.

Novo Nordisk's pill version of Wegovy has already delivered one of the most successful drug launches in history since its market debut earlier this year. With regulatory hurdles now cleared, Lilly will seek to capture market share from the established competitor, intensifying competition in the rapidly expanding obesity treatment sector.

The upcoming rivalry between these pharmaceutical heavyweights represents a significant business battle for control of the next frontier in metabolic disease treatment. As Leerink Partners analyst David Risinger noted, "It will be a battle royal for GLP-1 pill leadership between Novo and Lilly," with substantial market implications for both companies.